<?xml version='1.0' encoding='utf-8'?>
<document id="24247088"><sentence text="Characterization of a new degradation product of nifedipine formed on catalysis by atenolol: A typical case of alteration of degradation pathway of one drug by another."><entity charOffset="49-59" id="DDI-PubMed.24247088.s1.e0" text="nifedipine" /><entity charOffset="83-91" id="DDI-PubMed.24247088.s1.e1" text="atenolol" /><pair ddi="false" e1="DDI-PubMed.24247088.s1.e0" e2="DDI-PubMed.24247088.s1.e0" /><pair ddi="false" e1="DDI-PubMed.24247088.s1.e0" e2="DDI-PubMed.24247088.s1.e1" /></sentence><sentence text="An increasing interest is being shown throughout the world on the use of fixed-dose combinations of drugs in the therapy of select diseases, like cardiovascular diseases, due to their multiple advantages" /><sentence text=" Though the main criterion for combining drugs in a single dosage form is the rationale, but consideration like stability of formulation is equally important, due to an added aspect of drug-drug interaction" /><sentence text=" The objective of this study was to evaluate interaction among the drugs in an antihypertensive combination of nifedipine and atenolol"><entity charOffset="111-121" id="DDI-PubMed.24247088.s4.e0" text="nifedipine" /><entity charOffset="126-134" id="DDI-PubMed.24247088.s4.e1" text="atenolol" /><pair ddi="false" e1="DDI-PubMed.24247088.s4.e0" e2="DDI-PubMed.24247088.s4.e0" /><pair ddi="false" e1="DDI-PubMed.24247088.s4.e0" e2="DDI-PubMed.24247088.s4.e1" /></sentence><sentence text=" Nifedipine is a known light sensitive drug, which degrades via intra-molecular mechanisms to nitro- and nitroso-pyridine analogs, along with a few minor secondary products that are formed through inter-molecular interactions amongst primary degradation products and their intermediates"><entity charOffset="1-11" id="DDI-PubMed.24247088.s5.e0" text="Nifedipine" /><entity charOffset="105-121" id="DDI-PubMed.24247088.s5.e1" text="nitroso-pyridine" /><pair ddi="false" e1="DDI-PubMed.24247088.s5.e0" e2="DDI-PubMed.24247088.s5.e0" /><pair ddi="false" e1="DDI-PubMed.24247088.s5.e0" e2="DDI-PubMed.24247088.s5.e1" /></sentence><sentence text=" Atenolol is reasonably stable weakly basic drug that is mainly hydrolyzed at acetamide terminal amide moiety to its corresponding carboxylic acid"><entity charOffset="1-9" id="DDI-PubMed.24247088.s6.e0" text="Atenolol" /><entity charOffset="78-87" id="DDI-PubMed.24247088.s6.e1" text="acetamide" /><entity charOffset="97-102" id="DDI-PubMed.24247088.s6.e2" text="amide" /><entity charOffset="131-146" id="DDI-PubMed.24247088.s6.e3" text="carboxylic acid" /><entity charOffset="82-96" id="DDI-PubMed.24247088.s6.e4" text="amide" /><pair ddi="false" e1="DDI-PubMed.24247088.s6.e0" e2="DDI-PubMed.24247088.s6.e0" /><pair ddi="false" e1="DDI-PubMed.24247088.s6.e0" e2="DDI-PubMed.24247088.s6.e1" /><pair ddi="false" e1="DDI-PubMed.24247088.s6.e0" e2="DDI-PubMed.24247088.s6.e4" /><pair ddi="false" e1="DDI-PubMed.24247088.s6.e0" e2="DDI-PubMed.24247088.s6.e2" /><pair ddi="false" e1="DDI-PubMed.24247088.s6.e0" e2="DDI-PubMed.24247088.s6.e3" /><pair ddi="false" e1="DDI-PubMed.24247088.s6.e1" e2="DDI-PubMed.24247088.s6.e1" /><pair ddi="false" e1="DDI-PubMed.24247088.s6.e1" e2="DDI-PubMed.24247088.s6.e4" /><pair ddi="false" e1="DDI-PubMed.24247088.s6.e1" e2="DDI-PubMed.24247088.s6.e2" /><pair ddi="false" e1="DDI-PubMed.24247088.s6.e1" e2="DDI-PubMed.24247088.s6.e3" /><pair ddi="false" e1="DDI-PubMed.24247088.s6.e4" e2="DDI-PubMed.24247088.s6.e4" /><pair ddi="false" e1="DDI-PubMed.24247088.s6.e4" e2="DDI-PubMed.24247088.s6.e2" /><pair ddi="false" e1="DDI-PubMed.24247088.s6.e4" e2="DDI-PubMed.24247088.s6.e3" /><pair ddi="false" e1="DDI-PubMed.24247088.s6.e2" e2="DDI-PubMed.24247088.s6.e2" /><pair ddi="false" e1="DDI-PubMed.24247088.s6.e2" e2="DDI-PubMed.24247088.s6.e3" /></sentence><sentence text=" To the best of our knowledge, there is no known information on chemical compatibility among the two drugs" /><sentence text=" The present study involved subjecting of nifedipine, atenolol and their combination to a variety of accelerated and stress conditions"><entity charOffset="42-52" id="DDI-PubMed.24247088.s8.e0" text="nifedipine" /><entity charOffset="54-62" id="DDI-PubMed.24247088.s8.e1" text="atenolol" /><pair ddi="false" e1="DDI-PubMed.24247088.s8.e0" e2="DDI-PubMed.24247088.s8.e0" /><pair ddi="false" e1="DDI-PubMed.24247088.s8.e0" e2="DDI-PubMed.24247088.s8.e1" /></sentence><sentence text=" HPLC studies revealed formation of a new product in the mixture of two drugs (∼2%), which was also generated from nifedipine alone, but at trace levels (&lt;0"><entity charOffset="115-125" id="DDI-PubMed.24247088.s9.e0" text="nifedipine" /></sentence><sentence text="1%)" /><sentence text=" The product was isolated by preparative chromatography and subjected to indepth studies for its characterization" /><sentence text=" Ultra-violet, FT-IR, mass spectrometric and nuclear magnetic resonance spectroscopic studies highlighted that the principal photo-degradation pathway of nifedipine was modified and diverted in the presence of atenolol"><entity charOffset="154-164" id="DDI-PubMed.24247088.s12.e0" text="nifedipine" /><entity charOffset="210-218" id="DDI-PubMed.24247088.s12.e1" text="atenolol" /><pair ddi="false" e1="DDI-PubMed.24247088.s12.e0" e2="DDI-PubMed.24247088.s12.e0" /><pair ddi="false" e1="DDI-PubMed.24247088.s12.e0" e2="DDI-PubMed.24247088.s12.e1" /></sentence><sentence text=" To verify the same, a study was conducted employing two other β-blockers with similar structures to atenolol, and the same product was formed in relatively higher quantity therein also" /><sentence text=" The new product is postulated to be produced as a result of rearrangement of hydroxylamine intermediate, known to be involved in the generation of nitro- and nitroso-pyridine photo-degradation products of nifedipine"><entity charOffset="78-91" id="DDI-PubMed.24247088.s14.e0" text="hydroxylamine" /><entity charOffset="148-154" id="DDI-PubMed.24247088.s14.e1" text="nitro-" /><entity charOffset="159-175" id="DDI-PubMed.24247088.s14.e2" text="nitroso-pyridine" /><entity charOffset="206-216" id="DDI-PubMed.24247088.s14.e3" text="nifedipine" /><pair ddi="false" e1="DDI-PubMed.24247088.s14.e0" e2="DDI-PubMed.24247088.s14.e0" /><pair ddi="false" e1="DDI-PubMed.24247088.s14.e0" e2="DDI-PubMed.24247088.s14.e1" /><pair ddi="false" e1="DDI-PubMed.24247088.s14.e0" e2="DDI-PubMed.24247088.s14.e2" /><pair ddi="false" e1="DDI-PubMed.24247088.s14.e0" e2="DDI-PubMed.24247088.s14.e3" /><pair ddi="false" e1="DDI-PubMed.24247088.s14.e1" e2="DDI-PubMed.24247088.s14.e1" /><pair ddi="false" e1="DDI-PubMed.24247088.s14.e1" e2="DDI-PubMed.24247088.s14.e2" /><pair ddi="false" e1="DDI-PubMed.24247088.s14.e1" e2="DDI-PubMed.24247088.s14.e3" /><pair ddi="false" e1="DDI-PubMed.24247088.s14.e2" e2="DDI-PubMed.24247088.s14.e2" /><pair ddi="false" e1="DDI-PubMed.24247088.s14.e2" e2="DDI-PubMed.24247088.s14.e3" /></sentence><sentence text=" " /></document>